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Clinical Manifestations 
GENERAL FEATURES 
In Europe, sarcoidosis is the most frequently observed 
interstitial lung disease of unknown aetiology. The preva- 
lence rates range between 64 patients per 100 000 popula- 
tion in Sweden and nine patients in Italy, with intermediate 
numbers observed in Denmark (53 patients), Germany 
(43 patients), Ireland (40 patients), Norway (27 patients), 
The Netherlands (22 patients), the U.K. (20 patients), 
Switzerland (16 patients) and France (10 patients). For the 
Caucasian population of North America and Afro- 
Americans, the prevalence is three and 47 per 100 000, 
respectively (1). Sarcoidosis is a disease with protean mani- 
festations, and although the lung is most frequently 
involved, the disease can affect any organ of the body. The 
clinical manifestations are largely non-specific, as are the 
histological features. Patients with pulmonary sarcoidosis 
generally present to physicians because of non-specific 
constitutional complaints (e.g. fever, weight loss, fatigue, 
anorexia, malaise) and/or symptoms directly related to the 
chest (e.g. cough, dyspnoea, particularly with exertion, 
chest pain and, occasionally, haemoptysis). Early in the 
disease, the physical findings in the chest are usually limited 
to dry, crackling rales, most commonly heard at the 
posterior base of the lung. 
Although the onset of the disease is usually insidious and 
discovered in asymptomatic individuals by routine chest 
X-rays or heralded by constitutional complaints, it will 
occasionally manifest itself as a medical emergency. 
Involvement of the eye, the heart, the central nervous 
system or the development of hypercalcaemia may require 
immediate action. More than 90% of sarcoid patients will 
eventually develop pulmonary abnormalities easily recog- 
nizable on chest X-ray or tests of pulmonary function (2,3). 
The chest X-ray is rarely normal; most commonly it 
reveals bilateral hilar adenopathy and/or diffuse reticulo- 
nodular infiltrates in the parenchyma. Lung function tests 
usually reveal a loss in lung volumes (vital capacity and 
total lung capacity), a reduced diffusing capacity, and a 
mildly reduced arterial PO, that may diminish further with 
exercise. In general, the ratio of forced expiratory volume in 
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1 s to vital capacity is normal (4), although sensitive tests 
reveal airflow limitation (5) and ~20% of the patients 
present with unspecific bronchial hyperreactivity (6,7). 
DEFINITION 
An evaluation of transbronchial or open lung biopsies of 
patients in the early stage of sarcoidosis gives insight into 
why the patients suffer from the clinical findings outlined 
above. The typical findings are those of non-caseating 
granulomas within the alveolar, bronchial and vascular 
walls (S-10). These granulomas are diffusely scattered 
throughout the lung parenchyma. In contrast to the granu- 
lomas seen in hypersensitivity pneumonitis, the granulomas 
of sarcoidosis are well-formed, compact aggregates. They 
are usually of varying age, ranging from highly cellular 
lesions to collections with diminishing cellularity, some 
fibrosis, and progressive hyalinization. Two characteristic 
zones can be seen in a typical, well-developed sarcoid 
granuloma: (i) a central zone or follicle which is tightly 
packed with cells, composed primarily of macrophages, 
multinucleated giant cells, and epitheloid cells; and (ii) a 
peripheral zone containing loosely arranged cells like a 
collar of lymphocytes, monocytes and fibroblasts (Plate 1) 
(8,ll). Although many microscopic features may suggest 
sarcoidosis, the epitheloid granulomas, especially in their 
earlier stages, are indistinguishable from those of other 
idiopathic granulomatous disorders or even granulomatous 
disorders of known origin, such as berylliosis, tuberculosis 
or hypersensitivity pneumonitis. 
Thus, sarcoidosis is best defined in histopathological 
terms as ‘a disease characterized by the presence in all of 
several affected organs and tissues of non-caseating 
epitheloid-cell granulomas, proceeding either to resolution 
or to conversion into hyaline connective tissue’ (8). The 
clinical diagnosis, however, can only be supported by 
typical histopathological findings. Pathognomonic criteria 
or a diagnostic ‘gold standard’ are absent. Most authorities 
thus includes several clinical, radiological, immunological 
and histologic features into their diagnostic criteria since 
other disease processes can simulate sarcoidosis in many 
ways. Occasionally, all of these features may suggest the 
diagnosis of sarcoidosis in patients later proven to have 
other diseases (12). Therefore, rigorous efforts have to be 
made to exclude alternative diagnoses, e.g. tuberculosis, 
lymphoma, berylliosis, etc. (13-l@, and patients diagnosed 
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more severe the clinical findings at the time of diagnosis 
and the more organ systems are involved by the disease, 
the more frequent adverse courses have been observed. 
Cutaneous sarcoid frequently indicates chronic and dis- 
seminated involvement and the prognosis, in general, is 
poor in patients with advanced skin lesions (21-23). 
Only rough estimates of the mortality of untreated 
sarcoidosis are available. If untreated. it is associated with a 
mortality of ~5%. In a recent epidemiological study from 
Denmark with a median follow-up of 27 years, an excess 
mortality from sarcoidosis and sarcoidosis-related diseases 
in patients with advanced radiological findings and deterio- 
rated lung function was perceived in the first 20 years. 
Although the mortality of the sarcoid cohort was higher 
than that of the general population, the difference was not 
statistically significant (23,24). This number may differ in 
other ethnic groups (25,26) or cohorts with increased 
frequencies of certain manifestations. such as cutaneous 
sarcoidosis (27). 
PLATE 1. Light photomicrograph of a typical non- 
caseating granuloma with multinucleated giant cells. 
Staging of Inflammatory Activity 
as suffering from sarcoidosis must regularly be subjected to 
review and further testing (19). 
NATURAL COURSE OF THE DISEASE 
Most patients with diagnosed sarcoidosis will undergo 
clinical and radiological resolution of the disease over a 
period ranging from several months to a few years (20). A 
few develop a progressive form of the disease which may 
result in death (21). In those patients undergoing resolution, 
subsequent biopsy or material examined at necropsy reveal 
changes ranging from complete resolution with no scarring 
to focal pulmonary scars without evidence of granuloma 
formation. The fate of the sarcoid granuloma is morpho- 
logically well documented. It may appear fresh for months 
to years; however, the granuloma ultimately resolves, leav- 
ing no morphological changes, or it undergoes an oblitera- 
tive fibrosis. The fibrosis starts as a rim of collagen around 
the granuloma and proceeds in a centripetal fashion until 
the entire structure is replaced by fibrous tissue. The late 
stage of sarcoidosis is characterized by an extensive, patchy 
pulmonary fibrosis and a hypertrophy of pulmonary 
arteries (8,ll). 
The natural course of sarcoidosis is unpredictable in an 
individual patient; for example patients with advanced 
pulmonary infiltrates and splenomegaly may have spon- 
taneous recovery, whereas others with asymptomatic hilar 
adenopathy may develop severe disease. Extensive clinical 
and epidemiological studies performed since 1950 empha- 
size the generally favourable outcome of sarcoidosis. About 
70% of the patients presenting with hilar adenopathy alone 
(i.e. radiographic type I) have spontaneous resolution. In 
patients presenting with pulmonary infiltrates (types II and 
III; diffuse parenchymal infiltrates with (type II) or without 
(type III) hilar adenopathy), this figure is reduced to about 
50%. A 40% mortality rate was observed in those who 
presented with radiographic signs of fibrosis. Generally, the 
CLINICAL PARAMETERS 
For clinical purposes, a staging of the inflammatory activity 
of the disease is required after establishing diagnosis. 
Unfortunately, the best approach to this problem has not 
been determined. However, it is clear that the conventional 
approaches to staging patients, such as chest X-ray and 
lung function tests, are neither sensitive to, nor specific for, 
the inflammatory processes in the lower respiratory tract 
requiring pharmacological intervention. Thus, while the 
tests used to periodically evaluate sarcoidosis patients still 
include chest X-ray and lung function tests, it is now 
recognized that these tests tell the clinician about the extent 
of the damage to the lung parenchyma, but not about the 
activity of the inflammatory processes within the lower 
respiratory tract. A loss of lung function or a deterioration 
of X-ray findings over a period of time certainly indicate 
inflammatory active processes; however, the evidence is 
indirect and is obtained with considerable delay (2,9). 
Computed tomography is capable of revealing indicators of 
ongoing alveolitis or fibrosis; however, the clinical applica- 
bility of this approach remains to be established (28,29). 
BRONCHOALVEOLAR LAVAGE 
Due to the unpredictable course of sarcoidosis, staging 
parameters of prognostic value are required to enable early 
therapy in patients with poor prognosis and to avoid 
unnecessary therapy in those who will have a spontaneous 
regression of the disease. The percentage of lavage lym- 
phocytes and the CD4KD8 ratio within these cells have 
been shown to correlate with the spontaneous course of the 
disease, at least to some extent. Patients with acute disease 
and good prognosis have high numbers of lymphocytes 
with an elevated CD41CD8 ratio in their lavage, whereas 
patients with more chronic disease and risk of deterioration 
exhibit only moderately raised values (30-32). This finding 
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FIG. 1. Bronchoalveolar lavage (BAL) CD41CD8 ratio in groups of sarcoidosis patients with different active or inactive 
and acute or chronic sarcoidosis. Horizontal bars represent mean (thick bars) and one standard deviation (thin bars). 
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was reproduced in the author’s study population showing 
only a minor change in BAL cytology in those patients with 
chronic disease (Fig. 1). Due to the non-parametric distri- 
bution of the cells in normal BAL, generally accepted 
normal values do not exist (33-35). In addition, study 
populations investigated by different researchers differ in 
their ethnic composition, leading to a confounding by 
different clinical presentations (26,27), e.g. more chronic 
disease in blacks or different immunoresponse genes (25). 
Both facts may explain why BAL studies reveal so many 
conflicting results. 
The concept of testing functional parameters of lavage 
cells, i.e. interleukin-2 (IL-2) transforming growth factor p 
and tumour necrosis factor a (TNFa) release, or of com- 
bining these parameters with cytological findings for 
obtaining prognostic information is currently evaluated in 
the author’s laboratory (36). Encouraging results indicate 
that this approach allows the identification of subgroups of 
patients with good (37) and poor (38) prognosis (see part I 
of this review, published in this issue of Respiratory Medi- 
tine), although similar study designs have thus far failed to 
do so (39). These approaches exploit the accumulated 
knowledge of the immunopathogenesis of the disease, but 
the technical approach is far too complex for an application 
in every day practice; however, these studies give evidence 
of prognostic factors in the immunopathogenesis of the 
disease for which serum markers might be delineated in 
the future. 
SERUM MARKERS 
There is easy access to serum, and markers from this body 
compartment have been used to gauge sarcoidosis for many 
years. Angiotensin-converting enzyme (ACE) and lysozyme 
are the oldest serum markers of sarcoidosis (40,41), probing 
one aspect of the disease’s immunopathogenesis, i.e. the 
granuloma burden. Granuloma is a feature of many chronic 
interstitial lung diseases, e.g. sarcoidosis, hypersensitivity 
pneumonitis, berylliosis or histiocytosis X, and are struc- 
tured masses composed of activated macrophages and their 
derivates, i.e. epitheloid and giant cells. All these diseases 
may be associated with elevated serum levels of ACE and 
lysozyme. In contrast to the foreign body type granuloma, 
the sarcoid granuloma contains more lymphocytes and, at 
times, eosinophils, mast cells and fibroblasts. Sequential 
analysis of the cellular components of these lesions has 
demonstrated their dynamic nature. An influx, local multi- 
plication and cell death time of immune cells can be 
observed, most probably governed by inflammatory signals. 
In immune granulomas, as in sarcoidosis, these signals are 
likely to be cytokines and cellxell interactions of lym- 
phocytes, macrophages and their derivates, and fibroblasts 
(42). The transformation of macrophages to epitheloid cells 
is associated with the secretion of ACE and lysozyme; 
however, after stimulation by T-lymphocytes, alveolar 
macrophages are also known to release these molecules. 
Although local production by alveolar macrophages could 
be demonstrated (43,44), these molecules’ serum levels 
mainly indicate the granuloma burden of the total body as 
demonstrated by morphometry and quantitative mRNA 
analysis in an animal model of pulmonary granuloma (45) 
and clinical 67gallium scanning (46). Although ACE and 
lysozyme are frequently used, there is no correlation 
between their sernm level and response to treatment or 
prognosis. The initial values do not differ between patients 
who deteriorate and those who improve (47). Serum levels 
can, however, be used to monitor therapy (47). 
From the concept of the immunopathogenesis of sar- 
coidosis as described in part I of this review, a number of 
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serum markers measuring the activation of macrophages, 
T-lymphocytes and endothelial cells have been delineated. 
Neopterin, a small 250 kDa metabolite of the guanosi- 
netriphosphate pathway, is released by activated macro- 
phages and monocytes (48). It gauges the inflammatory 
activity of these cells rather than their activation in the 
course of building granulomas. As expected, elevated serum 
levels were found in sarcoidosis and are used to monitor the 
activity of cells of the macrophage/monocyte lineage (49- 
5 1). Interestingly, a correlation between BAL-cell-released 
TNFa or IL-6 with serum neopterin could not be observed 
(52) giving rise to the hypothesis that the elevated neop- 
terin levels are sequelae of cell activation in body compart- 
ments other than the alveolar space, such as lymph nodes 
providing secreted molecules with easy access to the serum. 
Nevertheless, serum or urine neopterin concentrations 
proved to be very useful clinical parameters to probe the 
activity of the cells of the monocyte/macrophage lineage in 
the course of sarcoidosis (4995153). 
Activated T-cells express an IL-2R 55 kDa175 kDa het- 
erodimer on their cell surface and release a soluble form of 
the 55 kDa chain (sIL-2R) (54,55). sIL-2R can be found in 
BAL fluid and serum of sarcoidosis patients, and it is 
released by activated alveolar immune cells (56659). In 
addition to lymphocytes, macrophages are capable of 
expressing IL-2R upon activation, and it has been demon- 
strated that up to 50”/0 of activated sarcoid alveolar macro- 
phages exhibit increased numbers of IL-2R (60). The 
relative contribution of lymphocytes and macrophages to 
the alveolar lining fluid sIL-2R concentration is not known 
(5860). The absence of a correlation between alveolar 
macrophage TNFa release as marker of cell activation and 
BAL fluid sIL-2R concentration argues in favour of sIL-2R 
being a T-lymphocyte marker (61). A major contribution of 
any BAL cell population to the sIL-2R serum level cannot 
be expected, as a leakage of the basal membrane or active 
transport mechanisms allowing a 55 kDa protein to leave 
the alveolar space has not been observed in sarcoidosis (62). 
In agreement with these findings, the sIL-2R serum concen- 
tration was found to be independent of alveolar immune 
cell activation, indicating that these cells are not the pre- 
dominant contributors to the exaggerated serum levels of 
sIL-2R (58). The debate about the contribution of IL-2R 
shedding by peripheral blood monocytes to the serum level 
has not been settled because quiescent, non-shedding and 
activated, shedding sarcoid peripheral blood mononuclear 
cells have been found in clinical investigations with large 
study populations (58,59,63). Nevertheless, monitoring 
T-cell activity within sIL-2R serum level reveals an intimate 
relationship between this parameter and the clinical activity 
of the disease, providing further evidence for the close 
linkage between the course of sarcoidosis and the activated 
state of T-cells (57760,64). Moreover, those patients with- 
out indications for therapy but with high sIL-2R serum 
levels indicating a T-cell activation in the course of sar- 
coidosis tend towards a progressing course with subsequent 
indications for corticoid therapy (36). In some study 
populations, sIL-2R and ACE serum levels correlate 
with each other (59,63), but other researchers could not 
reproduce this finding (57:64), which argues against the 
hypothesis that sIL-2R is derived from monocytes or 
alveolar macrophages. 
Another marker exclusively expressed and released by 
T-cells is sCD27, the soluble form of a receptor of the nerve 
growth factor receptorltumour necrosis factor receptor 
gene family (65). sCD27 is shedded after T-cell activation, 
and the amount of its soluble form is supposed to correlate 
with the number of activated T-cells. Elevated broncho- 
alveolar fluid and serum levels have been found in sarcoid- 
osis, and its use as a clinical marker has been suggested (66). 
Adenosine deaminase (ADA), an enzyme involved in the 
purin degradation, is widely distributed in human tissues, 
and its soluble form gives rise to elevated serum levels. It is 
related to lymphocytic differentiation and proliferation, 
showing a significant increase during an immune response. 
ADA shows high activity in epitheloid granulomas, and its 
concentration in pleural fluid correlates with T-cell number 
and markers of their activity (67,68). The latter is one of the 
reasons why it is considered to be a marker of cell-mediated 
immunity. Measuring ADA serum levels in sarcoidosis 
disclosed elevated concentrations in active disease (69,70) 
and a somewhat higher sensitivity than sIL-2R, ACE or 
neopterin (71). 
Epithelial cells of the lower respiratory tract, especially 
type II pneumocytes, are integrated into the pulmonary 
immune response as demonstrated by their constitutive 
expression of HLA-DR (72) and their expression of adhe- 
sion molecules such as CD54 (ICAM-l), CD51 and CD49d 
(73,74). In parallel with monokine release, an increased 
expression of adhesion molecules such as CD1 l/CD18 and 
intercellular adhesion molecule-l (ICAM-1) can be 
observed (75,76). The expression of ICAM- has been 
demonstrated on many cells, including endothelia in sar- 
coid tissue, supporting the hypothesis that the ICAM-l/ 
LFA-1 (leukocyte function antigen-l) pathway is involved 
in the extravasation of leukocytes into sarcoid lesions (77). 
ICAM- is shedded from the cell surface (sICAM-1) giving 
rise to elevated concentrations in body fluids (78) segregat- 
ing with the inflammatory activity of sarcoidosis (79,80). 
Although some evidence exists that sICAM-1 is shedded by 
immune cells (7998 l), the origin of the circulating sICAM-1 
in sarcoidosis is not known, as immune cell markers do not 
correlate with sICAM-1 serum levels (79,80). Thus, it has to 
be assumed that both epithelial and immune cells contrib- 
ute to the observed serum sICAM-1 (80) which impedes its 
clinical use. Furthermore, elevated sICAM-1 levels have not 
been found in sarcoidosis patients by all researchers (81,82), 
casting some doubt on the sensitivity of this marker. 
There is multiple histological and immunological evi- 
dence of the involvement of pneumocytes II (alveolar 
epithelial cells type II) in the immunopathogenesis of 
sarcoidosis (83,84). These cells seem to be capable of 
promoting (72,85) and dampening (8687) immunological 
reactions in the lower respiratory tract, and are integrated 
into the immunological cytokine network of the lung 
(85,88,89). The immunopathogenetical phenoma observed 
in pneumocytes and the basal membrane cause only 
few alterations in serum parameters. KL-6, a mutinous, 
high molecular weight glycoprotein, expressed on type II 
pneumocytes. is found elevated in the serum of patients 
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TABLE 1. Serum markers for the inflammatory activity of sarcoidosis 
Parameter 
Pathomechanism 
probed 
Clinical 
usage 
Literature 
(selected) 
Angiotensin-converting enzyme Granuloma burden, macrophages 
Lysozyme Granuloma burden, macrophages 
Carboxypeptidase N Granuloma burden, macrophages 
Neopterin Macrophages, monocytes 
Soluble CD14 Macrophages, monocytes 
Soluble interleukin-2 receptor T-cells 
Soluble CD27 T-cells 
Adenosine deaminase T-cells 
Soluble ICAM- Endothelia and immune cells 
KL-6 Pneumocytes 
Frequent 
Frequent 
Sporadic 
Limited 
Under investigation 
Limited 
Suggested 
Sporadic 
Suggested 
Suggested 
(43,45,47) 
(41,43) 
(49-51) 
(51,129) 
(36,57,58,63) 
(66) 
(69-71) 
(79-81) 
w491) 
with active pneumonitis, such as sarcoidosis, cryptogenic 
fibrosing alveolitis and hypersensitivity pneumonitis (90). 
Interestingly, these heightened serum levels correlate with 
alveolitis patterns found by computed tomographic (CT) 
scan and with a number of cellular parameters of BAL (91). 
Whether this serum marker is of any clinical value remains 
to be established, as other sources besides pneumocytes 
II have been identified (90). The serum markers are 
summarized in Table 1. 
FIBROSIS 
The poorest prognosis is found in patients with developing 
pulmonary fibrosis. Therefore, early markers of fibrosis are 
in demand to guide therapeutic interventions. In BAL, 
markers of connective tissue turnover, such as procollagen 
III peptide, vitronectin, fibronectin and collagenase, can be 
found (92-95) and much hope has been placed in these 
phenomena to serve as accurate predictors of fibrosis. 
Taken together, neither the release of cytokines able to 
stimulate fibroblast growth nor the increase in indicators of 
connective tissue turnover have been shown to predict 
fibrosis conclusively. They may instead be regarded as 
indicators of fibroblast activation and extracellular matrix 
remodelling in the course of inflammation and granuloma 
formation (95). Thus, the clinical corner stones for the 
identification of patients at risk for fibrosis remain inves- 
tigations such as testing of lung function, pulmonary 
compliance, CO diffusion and chest X-rays. 
Treatment 
The aetiology of sarcoidosis remains unknown and therefore 
no specific treatment is possible. Fortunately, many patients 
will not require treatment because the symptoms are not 
disabling and frequently remit spontaneously. Prompt initi- 
ation of corticosteroid therapy, however, is indicated when 
granulomas cause dysfunction in vital organs (e.g. heart, 
central nervous system, eyes, hypercalcaemia), or when the 
inflammation is particularly disabling or when disfiguring 
skin lesions emerge. While there is general agreement 
that corticosteroids should be administered to patients 
with extrapulmonary manifestations (96,97), the use of 
anti-inflammatory drugs in those with involvement of the 
respiratory system has, until recently, been under debate 
(98,99). A major obstacle in effectively treating pulmonary 
sarcoidosis is the inability to predict reliably which patients 
will recover and which will deteriorate. 
Judging by radiographical typing, corticosteroid therapy 
does not unequivocally change the long-term outcome of 
the disease (21,22,28,100). However, as mentioned above, 
radiography might not be the appropriate method for 
evaluating therapeutic effects, because it indicates organ 
damage and not inflammatory activity. In a prospective 
study by Hunninghake et al., only sarcoidosis patients with 
evidence of recent deterioration of lung function or severe 
extrapulmonary disease were treated with corticosteroids. 
Finding the indication for therapy on the basis of these 
clinical criteria, it was demonstrated that treatment pre- 
vented deterioration or induced improvement of lung 
function (20). Thus, the ongoing inflammatory processes 
causing deterioration of lung function can be obstructed, 
and further deterioration can be prevented. 
To achieve a selective delivery of the drug into the 
compartment most frequently involved and to reduce side- 
effects, inhalation has been proposed as an alternative way 
of administering of corticosteroids. Only a few studies have 
explored the role of inhaled corticosteroids in the manage- 
ment of sarcoidosis, and ambiguous results have been 
obtained. Patients with mandatory indications for cortico- 
steroids cannot be included in these studies, which makes it 
difficult to judge the efficacy of this therapeutic approach in 
study populations with only relative indications for therapy 
(101,102). The use of inhalative budenoside has been 
suggested for maintaining remission or for preventing 
further deterioration (101) but this interpretation of the 
study is under debate (103). Another study using a similar 
approach failed to demonstrate that the progression of 
sarcoidosis can be stopped by inhaled budenoside (102), 
leading to the conclusion that this therapeutic strategy 
requires further evaluation. 
Corticosteroids, like cyclosporin A, suppress critical pro- 
cesses in the immunopathogenesis of sarcoidosis, such as 
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the release of IL-2 by activated alveolar T-lymphocytes (see 
part I of this review) (101,102), but for cyclosporin A, 
unequivocal proof of therapeutic effectiveness in pulmonary 
sarcoidosis has not been obtained (104106), although 
a number of case reports demonstrating the benefits of 
cyclosporin A in corticosteroid-resistant cases have been 
published (107,108). Most interestingly, these case reports 
observe both the efficiency and failure of this drug in 
complicated chronic courses of sarcoidosis with extra- 
pulmonary manifestations such as skin (107) and central 
nervous system (109,110). Thus, cyclosporin A may serve as 
a second-line drug with corticoid-sparing capabilities for 
chronic sarcoidosis, but a commonly agreed definition of its 
role in the treatment of this disorder has not yet been 
reached. 
Numerous immunosuppressive or immunomodulating 
drugs, such as azathioprine, chlorambucil, chloroquine, 
cyclophosphamide, levalmisole and melatonin, have been 
evaluated with a view to serving as substitutes for corticos- 
teroids, but only ambiguous results have been obtained 
when used as monotherapeutic agents (96,108,111,112). As 
for cyclosporin A, the corticoid-sparing effects of these 
drugs are generally recognized and various combinations of 
prednisolone and immunosuppressants are used to lower 
the required dose of corticosteroids in the treatment of 
chronic sarcoidosis (108,113). 
In dermatology, chloroquine and hydroxychloroquine 
are used to treat non-infectious cutaneous manifestations in 
a number of diseases, including selected cases of sarcoidosis 
(114). Local, intralesional (115) and systemic (116.117) 
applications are used. In the latter, thorough ophthalmo- 
logical follow-up examinations are required to check for 
chloroquine-induced retinopathy, but with this precaution 
it is considered to be a safe therapy (116). 
In sarcoid macrophages, altered vitamin D3 metabolism 
is observed resulting in increased synthesis of the active 
vitamin which appears to be involved in the pathogenesis of 
hypercalcaemia, known to occur in sarcoidosis. ZIZ rit~o, 
chloroquine is capable of returning this altered metabolism 
to its normal state in which the presence of pro- 
inflammatory cytokines is required to enable macrophages 
to synthesize vitamin D3 (118). This finding explains the 
clinical observation that chloroquine or the combination of 
chloroquine and prednisone are effective measures for the 
treatment of sarcoid hypercalcaemia (119,120). 
Methotrexate has been sbown to reduce the inflamma- 
tory activity of alveolar macrophages when administered as 
treatment for sarcoidosis. Radical oxygen intermediates 
and TNFa release were significantly lower after treatment 
compared with measurements performed before metho- 
trexate treatment. In addition. under methotrexate, the 
percentage of BAL lymphocytes declined by about 50% and 
the CD4/CD8 ratio exhibited a downward trend. Both 
observations indicate that critical immunopathological 
mechanisms of alveolar macrophages and lymphocytes 
are dampened by this drug. In line with this finding, a 
therapeutic efficiency of methotrexate similar to that of 
prednisolone was observed (121). 
The intracellular mechanisms triggering TNFa gene tran- 
scription and action have been elucidated within the last 
few years, and some drugs originally developed for other 
indications were found to influene TNFa gene activation or 
the action of TNFa. It has been demonstrated that pentoxi- 
fylline (122) and thalidomide (123) inhibit the synthesis of 
TNFa and act synergistically with dexamethasone in the 
human system resulting in a lower TNFa serum level 
(124126). These findings led to the hypotheses that both 
pentoxifylline and thalidomide should be effective drugs in 
the treatment of pulmonary sarcoidosis. A recent study by 
Zabel et al. demonstrated in 11 of 18 patients with docu- 
mented disease progression that pentoxifylline is an effec- 
tive monotherapeutic agent capable of reversing the loss of 
pulmonary function (127). In addition, as deduced from in 
vitro studies, pentoxifylline can be used as a corticosteroid- 
sparing drug in those patients requiring high-dose pred- 
nisone to prevent disease progression (125,127). Carlesimo 
et nl. treated one patient with corticoresistant, cutaneous 
sarcoidosis and one patient with contraindications for 
prednisone with 100 mg thalidomide on alternate days, 
and observed disease regression with no relapse under 
maintenance therapy (128). 
Thus, the detailed knowledge of the immunopathogenesis 
of sarcoidosis mnakes it possible to design studies for finding 
new therapeutic options, as it has been demonstrated in the 
cases of methotrexate, pentoxifylline and thalidomide. 
Conclusion 
Immunological studies have advanced our understanding of 
the immunopathogenesis of interstitial lung diseases and. in 
particular, sarcoidosis. Some of the described mechanisms 
can be clinically applied to detect patients at risk of 
deterioration or to develop new therapeutic strategies. 
Using these approaches, methotrexate, pentoxifylline and 
thalidomide have been identified as drugs effectively sup- 
pressing sarcoid inflammation, and soluble IL-2 receptor 
serum level has been delineated to be a serum marker of 
sarcoid inflammation. Furthermore, analysing the pulmon- 
ary cytokine network in sarcoidosis will yield new staging 
parameters, possibly supplying prognostic information and 
guiding therapeutic interventions. 
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